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Previous studies have shown that exposure of cells to
Zn2 ions induces Ras and MAPK activation through the
EGF receptor (EGFR). To further determine the role of
EGFR in Zn2-induced signaling, mouse B82L fibro-
blasts expressing no detectable EGFR protein (B82L-
par), wild type EGFR (B82L-wt), kinase-deficient EGFR
(B82L-K721M), or COOH-truncated EGFR (B82L-c’958)
were tested. Exposure to Zn2 induced Ras activity in
B82L-wt, B82L-K721M, and B82L-c’958 but not in B82L-
par cells, indicating that the tyrosine kinase domain and
the auto-phosphorylation sites of the EGFR were not
required for Zn2-induced Ras activation. Zn2 induced
Src activation in all B82L cell lines, including B82L-par,
indicating that Src activation is independent of the
presence of the EGFR. A Src kinase inhibitor blocked
Zn2-induced Ras activation in all the B82L cell lines
capable of this response, suggesting the involvement of
Src kinase in Zn2-induced Ras activation via the EGFR.
Zn2 induced the association of the EGFR with Src and
specifically increased the phosphorylation of EGFR at
tyrosine 845 (Tyr-845), a known Src phosphorylation
site. Stably transfected B82L cells with a point mutation
of the EGFR at Tyr-845 (B82L-Y845F) exhibited only ba-
sal Ras activity following exposure to Zn2. These data
demonstrate that Src-dependent phosphorylation of the
EGFR at Tyr-845 is required for EGFR transactivation
and Zn2-induced Ras activation.
Zinc (Zn2), a Group IIb metal, is not only an essential
micronutrient involved in structural and regulatory cellular
functions (1) but also a common airborne metallic contaminant
that may contribute to the health effects of ambient and occu-
pational pollution (2–6). Recently, much attention has been
attracted to Zn2-induced intracellular signaling (7). Effects of
Zn2 ions on intracellular signaling molecules have been de-
termined, including Ca2 (8), mitogen-activated protein ki-
nases (2, 9), phosphatidylinositol 3-kinase (10), tyrosine ki-
nases such as the nonreceptor tyrosine kinase Src, and EGFR1
(11–13).
The EGFR family of receptor tyrosine kinases in mammals is
composed of four members: EGFR (ErbB1), ErbB2, ErbB3, and
ErbB4 (14). Of these, EGFR, an 1186-amino acid residue trans-
membrane glycoprotein (15), is the prototypal member of this
superfamily and is expressed in many cell types (16). Structur-
ally, EGFR consists of an extracellular ligand binding domain,
a single -helical transmembrane pass, an intracellular tyro-
sine kinase domain, and a COOH-terminal region that contains
autophosphorylation sites (15, 17–20). Upon binding of specific
polypeptide ligands, including EGF, transforming growth fac-
tor-, betacellulin, heparin-binding EGF, epiregulin, and am-
phiregulin, EGFR undergoes homo- or heterodimerization and
activation of its intrinsic tyrosine kinase activity (17, 21).
These events lead to the autophosphorylation of multiple tyro-
sine residues in the COOH-terminal tail of the molecule that
serve as binding sites for cytosolic signaling proteins contain-
ing Src homology 2 (SH2) domains and phosphotyrosine bind-
ing domains (20, 22).
Five sites of in vivo autophosphorylation have been identi-
fied in the EGFR: three major (tyrosines 1068, 1148, and 1173)
and two minor (tyrosines 992 and 1086) (18, 23–25). The bind-
ing of phosphorylated EGFR tyrosines with downstream sig-
naling proteins initiates multiple signaling cascades that cul-
minate in cell proliferation, migration, protein secretion,
differentiation, and/or oncogenesis (16). Among these signaling
pathways, the Shc/Grb2/Sos/Ras/MAPK cascade is a major mi-
togenic signaling pathway initiated by the EGFR (26). EGFR is
also part of signaling networks transactivated by stimuli that
do not directly interact with this receptor. These stimuli in-
clude agonists that specifically bind to other membrane recep-
tors, membrane depolarization agents, and environmental
stressors (27). The mechanisms for the transactivation of
EGFR vary with the cell type and stimuli (27).
Cellular Src functions as a co-transducer of transmembrane
signals emanating from a variety of growth factor receptors,
including EGFR (28–30). Evidence indicates that EGFR and
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the nonreceptor tyrosine kinase Src cooperate in both mitogen-
esis and transformation (28–32). Novel Src-phosphorylated ty-
rosine residues on the EGFR have been identified (33–35).
Our previous study showed that Zn2 ions induced EGFR
signaling in human airway epithelial cells (12). In this study,
we examined the mechanisms involved in Zn2-induced EGFR-
mediated signaling, especially the possible cooperation of
EGFR with Src. We found that an intact tyrosine at 845 of
EGFR (Tyr-845) was necessary for Zn2-induced Ras activa-
tion. However, the tyrosine kinase and autophosphorylation
sites within EGFR were dispensable. Furthermore, Zn2 was
found to activate Src kinase and induce its association with
EGFR. These results indicate that Ras activation triggered by
Zn2 is dependent on Src-mediated phosphorylation of EGFR
at Tyr-845.
EXPERIMENTAL PROCEDURES
Materials and Reagents—American Chemical Society-grade metal
salt Zinc sulfate was obtained from Sigma Chemical Co. (St. Louis,
MO). SDS-PAGE supplies such as molecular mass standards, polyacryl-
amide, ready gels, and buffers were from Bio-Rad (Richmond, CA).
Phospho-EGFR (Tyr-845), phospho-EGFR (Tyr-1068), and phospho-Src
(Tyr-416) antibodies were purchased from Cell Signaling Technology
(Beverly, MA). Monoclonal anti-EGFR antibody LA22, human recombi-
nant EGF, and anti-Src antibody (clone GD11) were purchased from
Upstate Biotechnology (Lake Placid, NY). Rabbit polyclonal anti-EGFR
antibody (1005), horseradish peroxidase (HRP)-conjugated goat anti-
rabbit or goat anti-mouse IgG were obtained from Santa Cruz Biotech-
nology (Santa Cruz, CA). Monoclonal anti-EGFR antibody Ab14 was
obtained from Neomarkers (Fremont, CA). PP1 was purchased from
BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA). Lipo-
fectAMINE transfection reagents were purchased from Invitrogen.
Cell Culture and Exposure—The B82L parental fibroblasts (B82L-
par) and B82L fibroblasts expressing the human wild type EGFR
(B82L-wt), kinase-defective EGFR (B82L-K721M), and the COOH-ter-
minally truncated EGFR at Tyr-958 (B82L-c’958) have been described
previously (36, 37). B82L-par fibroblasts were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal
bovine serum. A mutant dihydrofolate reductase gene provides a dom-
inant selectable marker for the B82L cells overexpressing the EGFR
(38, 39). These cells were maintained in the same medium containing 2
M methotrexate (39, 40). Prior to experiments methotrexate was re-
moved for at least 24 h. Confluent B82L cells were then incubated in
serum-free DMEM for 18–20 h before stimulation with zinc sulfate or
EGF.
A solution of 100 mM zinc sulfate was prepared in distilled water and
used as a stock for dilution into serum-free DMEM. The final concen-
tration of Zn2 was 500 M, and that of EGF was 100 ng/ml.
Stable Transfection with the EGFR-Y845F Construct—The EGFR
(Y845F) construct was described previously (34, 35). The B82L-par cells
were grown to 80% confluence and transfected with the EGFR (Y845F)
construct using LipofectAMINE (Invitrogen). Specifically, 10 g of the
plasmid DNA was incubated with 60 l of LipofectAMINE reagent for
30 min at room temperature. Transfection mixtures were diluted into
Opti-MEM I reduced serum medium (Invitrogen), and the diluted com-
plex solution was overlaid onto the subconfluent cells in 100-mm cul-
ture dishes. After incubating with B82L-par cells for 6 h at 37 °C, the
transfection mixture was removed and replaced with fresh DMEM
containing 10% fetal bovine serum. The transfected cells were passaged
in DMEM containing 1000 g/ml Geneticin (Invitrogen). After five
passages, several colonies were picked and characterized for EGFR
protein expression and phosphorylation using specific antibodies.
Immunoprecipitation and Immunoblotting—Confluent B82L cells
pretreated with vehicle or kinase inhibitor were treated with 500 M
Zn2 or 100 ng/ml EGF for 20 min. Cells were washed twice with
ice-cold phosphate-buffered saline (PBS) and lysed with RIPA buffer
(1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS, pH
7.4) containing 0.1 mM vanadyl sulfate and protease inhibitors (0.5
mg/ml aprotinin, 0.5 mg/ml trans-epoxy succinyl-L-leucylamido-(4-gua-
nidino)butane (E-64), 0.5 mg/ml pepstatin, 0.5 mg/ml bestatin, 10
mg/ml chymostatin, and 0.1 ng/ml leupeptin). After normalization for
protein content, cell extracts were subjected to SDS-PAGE on 11%
gradient PAGE gels or 4–15% Tris-HCl ready gels from Bio-Rad (Rich-
mond, CA) with a Tris-glycine-SDS buffer. Proteins were electro-blotted
onto nitrocellulose membrane. The blots were blocked with 3% nonfat
milk, washed briefly, incubated with phospho-specific antibodies in 3%
bovine serum albumin at 4 °C overnight, and then incubated with
HRP-conjugated secondary antibody for 1 h at room temperature.
Bands were detected using chemiluminescence reagents on film as
described previously (2).
Ras Activation Assay—A Ras activation assay kit was purchased
from Upstate Biotechnology (Lake Placid, NY). Ras activity was deter-
mined according to the supplier’s instruction. B82L cells treated with
zinc sulfate were lysed with 5  Mg2 lysis/wash buffer (MLB) (125 mM
HEPES, pH 7.5, 750 mM NaCl, 5% Nonidet P-40, 50 mM MgCl2, 5 mM
EDTA, and 10% glycerol). 500–1000 g of cell lysate was precleared
with glutathione agarose. 5 l of a 50% slurry of Raf-1 RBD (Ras
binding domain)-agarose was incubated with the lysate at 4 °C for 30
min. The agarose was collected by centrifugation and washed with MLB
three times and once with cold PBS, then boiled in 25 l of reducing
sample loading buffer. GTP-bound Ras protein was resolved by electro-
phoresis and transferred to nitrocellulose before being probed with a
mouse monoclonal anti-Ras (clone Ras10) antibody (1 g/ml). Protein
bands were visualized using a goat anti-mouse secondary antibody
conjugated to HRP and an enhanced chemiluminescence detection
system (12).
Co-immunoprecipitation of the EGFR with Src—Confluent B82L
cells were treated with zinc sulfate for 20 min and lysed with RIPA lysis
buffer. The lysates were pre-cleared with Protein A-Sepharose and
immunoprecipitated with agarose-conjugated anti-EGFR antibody for
1 h at 4 °C. Immune complexes were washed twice with RIPA buffer
and once with cold PBS. The immunoprecipitates were suspended in 25
l of 4 sample loading buffer (62.5 mM Tris-HCl, pH 6.8, 10% glycerol,
2% SDS, 0.7 M -mercaptoethanol, 0.05% bromphenol blue) and boiled
for 5 min before separation on 4–15% Tris-HCl ready gels. The protein
was transferred to a nitrocellulose membrane and incubated with anti-
Src mouse monoclonal IgG1 at 4 °C overnight. The EGFR-associated Src
bands were detected with HRP-conjugated goat anti-mouse secondary
antibody using ECL chemiluminescence regents as described above.
RESULTS
EGFR Mutants—Schematic representations of human wild
type EGFR and three EGFR mutants are shown in Fig. 1. The
three EGFR mutants include a construct encoding a kinase-
inactive receptor that contains a lysine to methionine substi-
tution at position 721 (B82L-K721M), which was involved in
ATP binding, a construct encoding a kinase-active receptor
truncated at Y958 (B82L-c’958), which lacks all five EGFR
FIG. 1. Schematic representation of the wild type and mutated
EGFRs. Locations of the extracellular domain, transmembrane region
(TM), tyrosine kinase domain (TK), Src phosphorylation site (Tyr-845),
and the tyrosine autophosphorylation sites (Tyr-992, Tyr-1068, Tyr-
1086, Tyr-1148, and Tyr-1173) are indicated. EGFR-wt, wild type re-
ceptor that has a functional kinase domain, an intact Src phosphoryl-
ation site, and all five autophosphorylation sites; EGFR-c’958, a COOH-
terminally truncated receptor at Tyr-958 that lacks all five
autophosphorylation sites; EGFR-K721M, a kinase-deficient receptor
that has a lysine to methionine point mutation at Tyr-721 that is
involved in ATP binding; EGFR-Y845F, a mutant receptor that has a
tyrosine to phenylalanine point mutation at Tyr-845 that is phospho-
rylated by nonreceptor tyrosine kinase Src.
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autophosphorylation sites, and a construct encoding a mutant
EGFR at Tyr-845 where the tyrosine residue is replaced with
phenylalanine (34, 35). No endogenous EGFR protein was de-
tected in B82L-par cells while other transfected B82L cells
express abundant EGFR protein (data not shown), which is
consistent with previous studies (37, 39, 41).
Zn2-induced Ras Activation in B82L Cells—To assess the
functional activation of EGFR, we used Ras as a downstream
marker of EGFR signaling. Ras activation assays showed that
exposure of B82L-par cells to Zn2 or to EGF did not increase
GTP-bound Ras after 20 min (Fig. 2A). In contrast, Zn2 in-
duced a significant increase in GTP-bound Ras in B82L-wt,
B82L-c’958 cells, or B82L-K721M (Fig. 2, B–D), confirming the
requirement for EGFR, as suggested by our previous study.
Interestingly, Zn2 increased GTP-bound Ras in cells express-
ing kinase-inactive and COOH-truncated EGFR demonstrat-
ing that neither the tyrosine kinase nor the autophosphoryla-
tion sites of EGFR were required for Zn2-induced Ras
activation. These results suggested that EGFR was transacti-
vated in Zn2-treated cells. In contrast, no increase in GTP-
bound Ras was detected in Zn2-treated B82L-Y845F cells
(Fig. 2E), indicating that EGFR tyrosine 845, which is phos-
phorylated by c-Src (35, 42), is required for Zn2-induced Ras
activation. EGF increased GTP-bound Ras in wt, kinase-inac-
tive K721M and to a lesser extent in c’958 EGFR-expressing
cells as previously repeated (39, 43, 44). EGFR Tyr-845 was not
required for EGF-induced Ras activation (Fig. 2E).
Requirement of Src Kinase Activity for Zn2-induced Ras
Activation—To investigate whether Src kinase mediated trans-
activation of EGFR in Zn2-exposed cells, we exposed cells to
PP1, a potent and selective Src kinase inhibitor (45). Pretreat-
ment with PP1 significantly blocked Zn2-induced Ras activa-
tion in B82L-wt (Fig. 3), whereas PP1 had no inhibitory effect
on EGF-induced Ras activation. These results indicate that Src
activity is required for Zn2- but not for EGF-induced Ras
activation. Similar results were obtained with B82L-c’958 or
B82L-K721M cell lines used in this study (data not shown).
To exclude the possibility that PP1 affected the intrinsic
kinase activity of EGFR, EGF-induced receptor autophospho-
rylation was examined in B82L-wt cells that were pretreated
with PP1. Consistent with previous reports (41, 46), PP1 had
no significant effect on EGF-induced EGFR autophosphoryla-
tion (data not shown).
Zn2-induced Phosphorylation of Src on Y416—To deter-
mine whether Zn2 affected c-Src, we examined the effects of
Zn2 on Src using a phospho-specific anti-Src (Y416) antibody.
Phosphorylation of Src Y416 is part of the enzyme activation
mechanism (47). As shown in Fig. 4, exposure to Zn2 for 20
min induced the phosphorylation of Y416 on Src in B82L-par
(Fig. 4A), B82L-wt (Fig. 4B), B82L-c’958 (Fig. 4C), and B82L-
K721M (Fig. 4D) cell lines. These results further support the
hypothesis that Src activation is involved in EGFR phospho-
rylation. Src phosphorylation was also detected in the B82L-
Y845F cell line (Fig. 4E) wherein the known Src phosphoryla-
tion site Tyr-845 on EGFR was replaced with phenylalanine.
These data indicated that activation of Src occurred independ-
ent of the existence of EGFR Tyr-845. In some cell types (B82L-
wt, B82L-K721M, or B82L-Y845F) EGF also increased phos-
phorylation of Src, and the magnitude of the increase was
always less than those induced by Zn2 (Fig. 4).
Zn2-induced Association of the EGFR with Src—Next, we
determined whether Zn2 induces a physical association be-
tween EGFR and Src in B82L-wt (Fig. 5A), B82L-c’958 (Fig.
5B), B82L-K721M (Fig. 5C), and B82L-Y845F (Fig. 5D) cell
lines. Immunoprecipitation of EGFR followed by immunoblot-
ting with anti-Src antibody revealed that treatment with Zn2
for 20 min caused a co-localization of EGFR with Src in these
cell lines. In contrast, treatment with EGF for 20 min did not
result in an interaction between Src and EGFR (Fig. 5).
Zn2-induced Phosphorylation of EGFR at Tyr-845 and Tyr-
1068—The finding that mutation of EGFR Tyr-845 prevented
Zn2-induced Ras activation suggested that phosphorylation of
this site was essential for transactivation of EGFR in cells
exposed to Zn2. To further test this hypothesis we examined
the phosphorylation of this site using a phospho-specific anti-
body to Tyr-845 of the EGFR. Zn2 induced phosphorylation of
EGFR at Tyr-845 in B82L-wt (Fig. 6A), B82L-c’958 (Fig. 6B),
and B82L-K721M (Fig. 6C) cells. EGF treatment also increased
the phosphorylation of Tyr-845 on EGFR in these cell lines. To
determine whether the phosphorylation of Tyr-845 is related to
Src activation induced by Zn2, the effect of PP1 on Zn2-
induced phosphorylation of EGFR Tyr-845 was also examined
in these cell lines. PP1 significantly blocked Zn2-induced
phosphorylation of EGFR Tyr-845 in all of the cell lines. In
contrast, PP1 only had a slight inhibitory effect on EGF-in-
duced EGFR phosphorylation at Tyr-845 in B82L-wt and B82L-
FIG. 2. Zn2-dependent Ras activation in B82L cell lines ex-
pressing wt and mutant EGFR. 80% confluent B82L-par (A),
B82L-wt (B), B82L-c’958 (C), B82L-K721M (D), and B82L-Y845F (E)
cells were starved in serum-free DMEM for 24 h before treatment with
500 M zinc sulfate or 100 ng/ml EGF for 20 min. Cells were lysed with
MLB, and lysates were immunoprecipitated with Raf-1 Ras binding
domain (RBD)-conjugated agarose. The immunoprecipitates were sub-
ject to 4–15% Tris-HCl ready gels. The membranes were blotted with
anti-Ras IgG2ak overnight and then incubated with anti-mouse HRP-
conjugated rabbit IgG. The optical densities of GTP-bound Ras bands
were quantified and normalized to that of control. Bar graphs summa-
rize at least three separate experiments.
FIG. 3. Effect of the Src kinase inhibitor, PP1, on Zn2-induced
Ras activation. Subconfluent B82L-wt cells were pretreated with 5 M
PP1 for 30 min and then stimulated with 500 M zinc sulfate or 100
ng/ml EGF for 20 min, respectively. Lysates were immunoprecipitated
with Raf-1 Ras binding domain (RBD)-conjugated agarose. The immu-
noprecipitates were subject to 4–15% Tris-HCl ready gels, and the
membranes were blotted with anti-Ras IgG2ak overnight and then in-
cubated with anti-mouse HRP-conjugated rabbit IgG. Data shown are
representative of three independent experiments.
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K721M cells. As expected, both Zn2 and EGF failed to induce
phosphorylation of EGFR Tyr-845 in B82L-Y845F cells. Addi-
tionally, the phosphorylation of EGFR Tyr-1068, a major EGFR
autophosphorylation site (23), was also examined in these cell
lines stimulated with Zn2 or EGF. As expected, no phospho-
rylation of Tyr-1068 in B82L-c’958 cells was observed (Fig. 7B).
In addition, Zn2 failed to induce the phosphorylation of EGFR
Tyr-1068 in B82L-wt (Fig. 7A), B82L-K721 (Fig. 7C), and
B82L-Y845F (Fig. 7D) cells. In comparison, EGF induced phos-
phorylation of EGFR Tyr-1068 in each cell type (Fig. 7, A, C,
and D).
DISCUSSION
Cross-communication between heterologous signaling sys-
tems is essential to integrate a variety of extracellular stimuli
into a limited number of signaling pathways (48, 49). EGFR
has been identified as a key element in the complex signaling
network that is transactivated by G protein-coupled receptors,
cytokine receptors, estrogen receptors, integrins, ion channels,
or stress-inducing agents (49–52). Accumulated evidence indi-
cates that Src kinases, calcium, the Ca2-regulated focal adhe-
sion kinase family kinase Pyk2, protein kinase C, Janus, and
tyrosine kinase Jak2 play crucial roles in the process of EGFR
transactivation (48, 53, 54). Moreover, the recent identification
of Zn2-dependent metalloproteinases and transmembrane
growth factor precursors as critical elements in G protein-
coupled receptor-induced EGFR transactivation pathways has
defined new components of a cellular communication network
of rapidly increasing complexity (51, 55, 56).
In the present study, the mechanisms for Zn2-induced
EGFR signaling were examined in B82L cells expressing wild
type, null, or modified versions of EGFR. These results show
that Zn2 ions induce Ras activation through a mechanism
that requires EGFR but not EGFR tyrosine kinase activity or
autophosphorylation sites. Furthermore, an intact tyrosine at
Tyr-845 on EGFR is required for Zn2-induced Ras activation.
Zn2-induced phosphorylation of the EGFR Tyr-845 residue
FIG. 4. Zn2 ions induce the phosphorylation of tyrosine 416 in
Src kinase. Confluent B82L-par (A), B82L-wt (B), B82L-c’958 (C),
B82L-K721M (D), or B82L-Y845F (E) cells were starved for 24 h and
then stimulated with 500 M zinc sulfate or 100 ng/ml EGF for 20 min.
Cell lysates were subject to Western blot using phospho-specific anti-
Src (Y416) antibody. Data shown are representative of three separate
experiments.
FIG. 5. Co-precipitation of EGFR with Src. Confluent B82L-wt
(A), B82L-c’958 (B), B82L-K721M (C), or B82L-Y845F (D) cells were
starved for 24 h prior to the treatment with 500 M zinc sulfate or 100
ng/ml EGF for 20 min. Cell lysates were precipitated by EGFR antibody
as described under “Experimental Procedures.” The precipitates were
subjected to immunoblot analysis using anti-Src antibody. EGFR-asso-
ciated Src was determined as described above. Data shown are repre-
sentative of three independent experiments.
FIG. 6. PP1 blocked Zn2-induced phosphorylation of EGFR
Y845. Subconfluent B82L-wt (A), B82L-c’958 (B), or B82L-K721M (C),
or B82L-Y845F cells (D) cells were starved in serum-free DMEM for
24 h prior to pretreatment with 5 M PP1 for 30 min and then stimu-
lated with 500 M zinc sulfate or 100 ng/ml EGF for 20 min, respec-
tively. Cells were lysed with RIPA buffer, and cell lysate proteins were
resolved with SDS-PAGE. Phosphorylated Tyr-845 on EGFR was ana-
lyzed using phospho-specific EGFR antibody (Tyr-845). Stripped mem-
branes were blotted with EGFR antibody. Data shown are representa-
tive of three independent experiments.
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requires Src activation. These data suggest that Zn2-induced
EGFR transactivation occurs through an Src-dependent
pathway.
Src phosphorylation of EGFR has been mapped to most of the
five autophosphorylation sites as well as other novel sites (50).
Tyr-845 in the EGFR is not a known autophosphorylation site
and has been shown to be phosphorylated by Src both in vivo
and in vitro (34, 57). Our data support a direct phosphorylation
of EGFR by c-Src for the following reasons: First, Zn2 ions
induce co-localization of EGFR with Src and Src phosphoryla-
tion of Tyr-845 has been reported to occur in an EGFRSrc
complex (57). The c-Src SH2 domain can bind activated EGFR
specifically and directly (58–60), which suggests other kinases
may not be necessary to mediate the phosphorylation of Tyr-
845 (34). Other Src-dependent or -independent residues on
EGFR may act as docking sites for Src or facilitate the associ-
ation of EGFR with Src, leading to Src phosphorylation of
Tyr-845 (33, 34). However, phosphorylation of Tyr-845 is only
one of multiple Src effectors, because Zn2 still induced phos-
phorylation of Src in the absence of Tyr-845 in B82L-Y845F
cells. Second, Src activity is required for the phosphorylation of
Tyr-845 as demonstrated with the use of a pharmacological
inhibitor of Src kinase activity (PP1). Overexpression of wild
type or kinase-deficient Src constructs by other investigators
produced results that agreed with these findings (34, 35). The
observation that EGF induced a greater extent of tyrosine
phosphorylation at Tyr-845 than Zn2 is likely due to ligand-
induced conformational changes that enhance accessibility of
this residue (61).
Zn2 ions induced Ras activation in cells expressing kinase-
inactive or truncated EGFR where Tyr-845 of EGFR is struc-
turally intact and can be phosphorylated, suggesting that Tyr-
845 provides a site of interaction with downstream effectors in
Zn2-induced Ras activation. ErbB2, a preferred dimerization
partner of all ErbB proteins (62, 63), may be involved in EGF-
dependent signaling in cells overexpressing aberrant EGFR
(36, 44, 64). Phosphorylation of EGFR Tyr-1068 by EGF in
B82L-K721M cells implied that ErbB2 might play a certain
role in EGF-induced signaling (44). We have observed that
Zn2 ions and EGF can activate ErbB2 in B82L-wt and B82L-
c’958 cells (data not shown). This hypothesis will be examined
using specific cell lines with or without expression of ErbB2
(65) in our laboratory. Although Tyr-845 of EGFR was neces-
sary for Zn2-induced Ras activation, this site is dispensable
for Zn2-induced EGFR-Src co-localization, because Zn2 still
induced EGFR-Src association in B82L-Y845F cells. Thus, we
hypothesize that other sites on EGFR may act as the docking
sites for EGFR-Src interaction. Whether there exists a scaffold-
ing protein to assemble these elements remains unknown, al-
though caveolin-1 has been reported to serve as an anchoring
site for various signaling molecules in B82L fibroblasts (41, 66).
Differences in Ras activation by Zn2 ions and EGF likely
reflect differences in the manner in which EGFR is utilized by
these stimuli. First, the autophosphorylation sites in the EGFR
are unnecessary for Ras activation induced by Zn2. Unlike
EGF, Zn2 ions do not induce the autophosphorylation of Tyr-
1068 in the EGFR. Second, the Tyr-845 residue is required for
Zn2- but not for EGF-induced Ras activation. The phospho-
rylation of Tyr-845 induced by Zn2 ions, but not that induced
by EGF, is dependent on Src activity. Therefore, Src activation
and subsequent phosphorylation of Tyr-845 are crucial steps in
the process of Zn2-induced Ras activation. Other tyrosine
phosphorylation sites play a significant role in EGF-induced
Ras activation. We have observed a baseline of GTP-bound Ras
in all B82L cell lines, which could be suppressed by the Src
kinase inhibitor, suggesting that constitutive Src activity may
be responsible for the basal activation of Ras.
In summary, this study describes a novel mechanism for
metal-induced EGFR transactivation, which is likely to be me-
diated by Src through the phosphorylation site of Tyr-845 on
EGFR.
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